
prostate cancer | Research | 11 pages | source: Lancet oncology | Added Aug 14, 2022
Use of Radionuclide and hybrid imaging in the assessment of recurrent prostate cancer
This article analyzes the latest information on imaging tests used in checking for prostate cancer recurrence. Radionuclide imaging and hybrid imaging are among the imaging tests reviewed in this article.


infertility & reproductive technologies | Research | Treatment | 10 pages | source: Frontiers in Endocrinology | Added Aug 14, 2022
Evaluating the effects of different antioxidants on the sperm quality and pregnancy rate of male infertility without a clear cause.
This study evaluated the effects of different antioxidants on sperm quality and the pregnancy rate of male infertility without a clear cause. The data showed that L-Carnitine had the highest probability of being the most effective antioxidant to increase sperm motility (movement) and sperm shape. ω-3 fatty acid had the highest probability of being the most effective antioxidant to improve sperm concentration.

hodgkin's lymphoma | Research | 10 pages | source: Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer | Added Aug 14, 2022
Evaluating the mental function in long-term survivors of Hodgkin lymphoma.
This study evaluated the cognitive (mental abilities) function of long-term survivors of Hodgkin lymphoma (HL). The data showed that long-term survivors of HL with inactive employment status and older age showed impaired cognitive function.

prostate cancer | Expertise | 0 pages | source: Patient Power | Added Aug 12, 2022
Advice for Moving Beyond the Shock of an Advanced Prostate Cancer Diagnosis
Diagnosed with advanced prostate cancer at age 53, Joe felt like he was hit by a Mac truck and prepared for the worst. Now, five years later, Joe is doing well and his PSA is undetectable. Joe and his wife, Yolanda, share their story and explain the tools that helped Joe move past the initial fear of his diagnosis.
Transcript
Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.
Joe:
Well, hi, I’m Joe. And in May of 2010, I was sitting at my desk, and I got a call from my primary care physician. And I had been going to him for a while because my PSA was high, and we did a biopsy, and so—well, let me back up.
It was my urologist that called me. And he says, “Joe? I’m sorry to tell you, you have cancer.” And I felt like a Mac truck hit me. I was in the prime of my life. I was 53 years old. I’m 58 now. Things were going well. Life was great. And I was one of those kind of guys, unlike you’re gonna hear from Bill, that I start spiraling down.
I told my supervisor that I was gonna go home, that I had been diagnosed with cancer. And I don’t even remember how I got home. I work downtown. I live about maybe 12, 13 miles away, and all I can remember is pulling up into the driveway. I don’t even remember how I got there. I drove myself, but I was just so consumed with that information that I had just received that I just sort of thought it was over.
I thought the worst. As I was going out, a colleague of mine said, “Hey, what’s going on? What’s wrong with you?” And I told this colleague that, and they said, “Yeah. So-and-so had that. He had that a few years ago. You want me to have him give you a call?” And I said, “Yeah, yeah. Whatever.” So I remember saying that, but by the time I pulled up into the driveway, this gentleman called me on my cell phone.
And he kinda brought me back from the ledge at that point. And so the rest is history. I ultimately got into MD Anderson. I was part of a trial. I didn’t give any hesitation to being a part of that. I sort of tried to ensure that I didn’t think about the worst, even though it was difficult for me not to do that.
So it was scary for me when I heard that not only did I have prostate cancer, but I had advanced prostate cancer. And so I tried not to think about that. And so when the doctor put me in the trial, you sign all this paperwork about things, as the doctor said earlier, that potentially could happen, the side effects.
All that stuff made me nervous. And then the packet itself had advanced prostate cancer on it. And I was thinking to myself, they couldn’t be talking about me. They must be talking about somebody else. So I kinda put that out of my mind and went through the trials, and had the side effects. I did experience quite a few side effects. But I had the support of my wife, and in the trials, we had frequent appointments here at MD Anderson.
And I had my wife with me, because I don’t know if it was—I was on hormones as well as a chemo drug, so I don’t know if it was the hormones or the chemos, but I couldn’t remember everything that the doctor would tell me. So they told me to bring a pad. I would have my wife jot down our conversations, our meetings with the doctors. And often at night, I would ask her, “Are you sure that’s what the doctor said?” So it was really scary for me.
But through my spirit, my relationship with the Holy Spirit, I’m here five years later, and I’m one of those lucky ones. I’m cancer free. My PSA is undetectable. And but…
Thank you. Thank you very much.
Yolanda:
Hi, my name is Yolanda, and I’m Joe’s wife.
Jeff Folloder:
And Joe’s wife. I’m gonna assume that means you’re his care provider. Was your husband an easy patient to deal with?
Yolanda:
Yes and no.
Jeff Folloder:
Let’s hear about the no first.
Yolanda:
He was one of those that—you brought the issue up earlier about having access to information, because MD Anderson provides you as a patient with a number, and you can go on and look at your results at your convenience.
And he would not only look at the results but provide additional interpretation to what the doctor had given him.
Jeff Folloder:
Google is your friend.
Yolanda:
And that wasn’t good, because it made him really antsy about his prognosis. So that was the not good part. Now…
Jeff Folloder:
Okay, what about the good part, though
Yolanda:
…he was really good at being a patient in that he’s not the typical male patient.
He’s very good at communicating, as you’ll see today. He talks more than I do, and he really makes sure you understand his concerns because he does ask. And he’s very good about making sure that he has a clear understanding, or that at least I got it if he didn’t.


prostate cancer | Research | Treatment | 6 pages | source: Urologic oncology | Added Aug 10, 2022
BMI and surgical outcomes after prostate removal
This study evaluated the effect of body mass index (BMI) on the outcomes of surgical removal of the prostate gland (radical prostatectomy) among prostate cancer patients.


prostate cancer | Research | Lifestyle | 10 pages | source: BJU international | Added Aug 08, 2022
Exercise, body composition and fatigue with androgen deprivation therapy
This study aimed to determine whether body composition (lean and fat mass) and exercise had an effect on fatigue levels in men treated with androgen deprivation therapy. The study concluded that fat mass was associated with fatigue, and an increase in lean mass due to exercise successfully reduced fatigue.


prostate cancer | Research | Treatment | 10 pages | source: Journal of clinical oncology | Added Aug 06, 2022
What are the cardiovascular risks of surgical castration compared to hormone therapy?
This study aimed to compare the risk of cardiovascular incidents (CIs, side-effects) of surgical castration versus castration achieved by hormone therapy. The study concluded that CIs were higher for surgical treatment at 1.5 years after treatment, but similar thereafter.


prostate cancer | Research | Treatment | 10 pages | source: Acta Oncologica | Added Aug 04, 2022
Comparing two hormone therapy drugs in men with advanced, non-metastatic prostate cancer
This study aimed to compare two hormone therapies, gonadotropin-releasing hormone (GnRH) agonists and anti-androgen therapy (AA) in men with advanced, non-metastatic prostate cancer. This study found that the two therapies have similar outcomes, but by starting with AA treatment may reduce side effects associated with GnRH medication.

prostate cancer | Research | 12 pages | source: Journal of clinical oncology | Added Aug 02, 2022
Utility of genomic scoring in prostate cancer
The authors evaluated a scoring system known as genomic classifier (GC) score that could indicate spread of cancer in prostate canecr patients after surgery and radiation therapy.

prostate cancer | Research | 8 pages | source: Urologic oncology | Added Jul 31, 2022
Proteins can predict bone tumors and survival in hormone-resistant prostate cancer
The authors aimed to determine whether specific proteins can predict bone tumors and death in patients with hormone-resistant prostate cancer.